Bioline RX ISIN: US09071M2052 Forum: Aktien Thema: Hauptdiskussion

🧐

WOW

und auch hier nachgelegt…

🚀🚀🚀🚀🚀🚀

😁🥁💤 aufgehts ...

was ist hier los seit dieser Woche 🤔

Da ist wieder Druck auf dem Kessel 🙂

🤝

BioLineRx: A Top Candidate For A Takeover Before 2022 Ends https://seekingalpha.com/article/4437317-biolinerx-a-top-candidate-for-a-takeover-before-2022-ends Summary • On May 4, the company crossed successfully a crucial hurdle, putting it en-route toward getting an FDA approval as early as next year. • As is the case with all micro-cap biotechs, investors remain skeptical due to the expected cash burn until, surely after, a possible approval. • Not only does BioLineRx has sufficient liquidity for the next two years, but there are additional catalysts along the next 18 months. • We believe that BLRX has a good chance to be bought out for a stock price in the mid-high teens, possibly before 2022 comes to an end. ...

👌

Also bei mir sind keine weiteren Gebühren angefallen.

Frage an die Investierten: werden Euch für die ADR‘s eigentlich bei Eurem Broker neben den normalen Ordergebühren noch extra Gebühren in Rechnung gestellt?

Und bekommen 😎

Mal mit zittrigem Finger vorhin eine kleine Position geordert…🙈

Oppenheimer and Wainwright gaben heute die Bewertung für Bioline von 14$ und 19$

BioLineRx Reports First Quarter 2021 Financial Results and Provides Corporate Update https://www.prnewswire.com/il/news-releases/biolinerx-reports-first-quarter-2021-financial-results-and-provides-corporate-update-301299676.html - Phase 3 GENESIS study in stem-cell mobilization (SCM) demonstrated highly statistically significant positive results across all primary and secondary endpoints - - ~90% of patients in treatment arm underwent transplantation following only one dose of Motixafortide and only one apheresis session; potentially positions Motixafortide + G-CSF to become new standard of care in this indication - - Company proceeding with activities in support of NDA submission targeted for H1 2022 - ... BioLine Rx Q1 EPS $(0.02) Beats $(0.15) Estimate https://www.benzinga.com/news/earnings/21/05/21294214/bioline-rx-q1-eps-0-02-beats-0-15-estimate BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.15) by 86.67 percent. This is a 50 percent increase over losses of $(0.04) per share from the same period last year.